Position in EXEL
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$1,133,968
-$52,466 QoQ
Shares Held
26,439
-2.3% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 96.21770868792314.ToString("F0")%
Shared 0.ToString("F0")%
None 3.782291312076856.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GRANDFIELD & DODD, LLC holds $47,624,275 across 12 Biotechnology names. EXEL ranks #5 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,415 | $28,135,685 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
21,704 | $9,691,704 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
37,326 | $2,802,809 | |
| 4 | INCY |
Incyte Corp
|
20,885 | $1,965,696 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
26,439 | $1,133,968 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,081 | $1,019,410 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
17,861 | $1,008,967 | |
| 8 | GMAB |
Genmab A/S
|
37,163 | $997,083 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,133,968 | 26,439 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $1,186,434 | 27,069 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $1,115,141 | 27,001 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $1,163,756 | 26,401 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $972,140 | 26,331 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $728,137 | 21,866 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $311,919 | 12,020 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||